Lil­ly’s Verzenio just miss­es the mark on over­all sur­vival in PhI­II breast can­cer study

Eli Lil­ly’s CDK4/6 in­hibitor Verzenio bare­ly missed the over­all sur­vival end­point in a Phase III clin­i­cal tri­al for ad­vanced breast can­cer.

In the MONARCH 3 study, 493 women re­ceived ei­ther Verzenio plus an aro­matase in­hibitor or place­bo plus an aro­matase in­hibitor as a first op­tion for their HR+, HER2- ad­vanced breast can­cer. The women in the Verzenio arm lived a me­di­an of 13 months longer than those in the place­bo arm — rough­ly 5.6 years com­pared to 4.5 years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER